Trial Profile
Phase II Study of Adjuvant Nivolumab in Patients With Resected Stage IIB/IIC Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 29 Nov 2022 Planned End Date changed from 1 Oct 2023 to 1 Jun 2024.
- 29 Nov 2022 Planned primary completion date changed from 11 Oct 2022 to 31 Dec 2023.
- 08 Jun 2021 Results (n= 23) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.